All-Oral Regimen Demonstrates Benefits, Safety in AML Subset

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

Related Keywords

China ,Harinder Gill ,School Of Clinical Medicine ,National Cancer Institute ,Department Of Medicine ,University Of Hong Kong ,Clinical Medicine ,Hong Kong ,Cash ,Aml ,Acute Myeloid Leukemia ,Leukemia ,